• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

ElmediX wants to stop coronavirus by heating patients in a controlled manner

Mechelen, Belgium, 24 March 2020 - The coronavirus has brought the whole world to a standstill. The Belgian company ElmediX wants to contain the virus with intensive heat treatments for corona patients. Controlled heating to 41.5 °C for three hours can inactivate the virus and activate the patient's immune system. ElmediX has launched a call to researchers and doctors and makes the technology available in the fight against the coronavirus.
Pharmaceutical company Janssen Pharmaceutica and gin distillery Filliers Distillery are making disinfectant hand gel from Sunday. They will distribute it among the Belgian hospitals.
At the University of Antwerp, twelve product developers are working day and night to develop oral masks. "Together with industrial partners, we try to set up an emergency production for protective equipment for health workers during this corona crisis".
The Bill & Melinda Gates Foundation is to provide samples of 15,000 therapeutic molecules to the Gasthuisberg hospital at the University of Leuven, to aid research into therapies to combat the coronavirus COVID-19, De Standaard reports.
Earlier this year, the lab of Xavier Saelens (VIB-UGent) announced the discovery of a unique antibody that is capable of binding the virus that causes COVID-19 (SARS-CoV-2). The antibody was developed in collaboration with two research groups in the US. The team has now established that the antibody can neutralize a lab variant of the virus, an important step forward in the development of a potential antiviral drug against the new coronavirus. This progress was made possible thanks to the intensive efforts of various teams in the VIB-UGent Center for Medical Biotechnology.
Augustine Therapeutics is one of VIB’s latest spinoffs, developing a first-in-class drug for Charcot-Marie-Tooth disease. The company recently announced a seed-funding round of €4.2 million, led by V-Bio Ventures. We spoke to several of the key persons in Augustine about how the startup is tackling the “Valley of Death”: the no-man’s-land between academia and industry where many potential therapies often fail.
Leuven, Belgium, Feb 20th 2020 - Montis Biosciences announces its launch with €8,4 million in seed financing from an international investor syndicate to investigate interactions between perivascular macrophages and tumor vasculature. The company’s mission is to exploit these cellular interactions with therapeutics to drive and sustain immune reactions against solid tumors.
Inari Agriculture has been awarded the 2020 Newcomer of the Year Trophy by Flanders Investment & Trade (FIT). Inari (US) opened its first foreign R&D branch in Ghent’s biotech valley just over a year ago. Since then, the Belgian team has been hard at work developing plants that can address both growing global food requirements and climate change. They’re approaching the challenge with both the latest genetic techniques and with a fresh perspective on how a business should be run.
Ghent, Belgium, February 10, 2020 - PharmaFluidics NV, an innovative player in the field of analytical chromatography, announces a product range extension into capillary flow rate liquid chromatography (capillary LC).  PharmaFluidics initiates commercial supplies of its new µPAC™ capLC column, bringing unprecedented sensitivity, reproducibility and robustness to a new range of customers worldwide, including the biopharmaceutical industry. PharmaFluidics’ unique high-resolution µPAC™ micro-Chip technology enables separation and detection of individual compounds in complex biological samples such as biopsies, proteome digests, culture media or biopharmaceutical actives, with unmatched precision.
Researchers have developed a new antibacterial strategy that weakens bacteria by preventing them from cooperating. The method involves attacking the protective biofilm produced by the whole bacterial colony, rather than the individual bacteria themselves. Because this results in non-resistant bacteria outcompeting their antibiotic resistant neighbors, the strategy does not promote the development of further resistance.
  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Mechelen, Belgium, 24 March 2020 - The coronavirus has brought the whole world to a standstill. The Belgian company ElmediX wants to contain the virus with intensive heat treatments for corona patients. Controlled heating to 41.5 °C for three hours can inactivate the virus and activate the patient's immune system. ElmediX has launched a call to researchers and doctors and makes the technology available in the fight against the coronavirus.
Pharmaceutical company Janssen Pharmaceutica and gin distillery Filliers Distillery are making disinfectant hand gel from Sunday. They will distribute it among the Belgian hospitals.
At the University of Antwerp, twelve product developers are working day and night to develop oral masks. "Together with industrial partners, we try to set up an emergency production for protective equipment for health workers during this corona crisis".
The Bill & Melinda Gates Foundation is to provide samples of 15,000 therapeutic molecules to the Gasthuisberg hospital at the University of Leuven, to aid research into therapies to combat the coronavirus COVID-19, De Standaard reports.
Earlier this year, the lab of Xavier Saelens (VIB-UGent) announced the discovery of a unique antibody that is capable of binding the virus that causes COVID-19 (SARS-CoV-2). The antibody was developed in collaboration with two research groups in the US. The team has now established that the antibody can neutralize a lab variant of the virus, an important step forward in the development of a potential antiviral drug against the new coronavirus. This progress was made possible thanks to the intensive efforts of various teams in the VIB-UGent Center for Medical Biotechnology.
Augustine Therapeutics is one of VIB’s latest spinoffs, developing a first-in-class drug for Charcot-Marie-Tooth disease. The company recently announced a seed-funding round of €4.2 million, led by V-Bio Ventures. We spoke to several of the key persons in Augustine about how the startup is tackling the “Valley of Death”: the no-man’s-land between academia and industry where many potential therapies often fail.
Leuven, Belgium, Feb 20th 2020 - Montis Biosciences announces its launch with €8,4 million in seed financing from an international investor syndicate to investigate interactions between perivascular macrophages and tumor vasculature. The company’s mission is to exploit these cellular interactions with therapeutics to drive and sustain immune reactions against solid tumors.
Inari Agriculture has been awarded the 2020 Newcomer of the Year Trophy by Flanders Investment & Trade (FIT). Inari (US) opened its first foreign R&D branch in Ghent’s biotech valley just over a year ago. Since then, the Belgian team has been hard at work developing plants that can address both growing global food requirements and climate change. They’re approaching the challenge with both the latest genetic techniques and with a fresh perspective on how a business should be run.
Ghent, Belgium, February 10, 2020 - PharmaFluidics NV, an innovative player in the field of analytical chromatography, announces a product range extension into capillary flow rate liquid chromatography (capillary LC).  PharmaFluidics initiates commercial supplies of its new µPAC™ capLC column, bringing unprecedented sensitivity, reproducibility and robustness to a new range of customers worldwide, including the biopharmaceutical industry. PharmaFluidics’ unique high-resolution µPAC™ micro-Chip technology enables separation and detection of individual compounds in complex biological samples such as biopsies, proteome digests, culture media or biopharmaceutical actives, with unmatched precision.
Researchers have developed a new antibacterial strategy that weakens bacteria by preventing them from cooperating. The method involves attacking the protective biofilm produced by the whole bacterial colony, rather than the individual bacteria themselves. Because this results in non-resistant bacteria outcompeting their antibiotic resistant neighbors, the strategy does not promote the development of further resistance.